06/10/2026
🚀 A major milestone for Archeon Medical 🚀
Archeon Medical secures $9M (€7.5M) Series A to advance clinical validation of ventilation system for cardiac arrest patients.
This funding will accelerate the clinical validation and commercial scale-up of EOlife, our real-time ventilation feedback device designed to improve cardiac arrest resuscitation survival and neurological outcomes.
Newfund, through its HEKA fund, led the round with participation from new investors funds managed by Eiffel Investment Group and UI Investissement (OSER BFC fund), alongside existing investors Majycc Innovation Santé - UI Investissement Innovation Santé and Karot Capital.
🔬 What's next?
The proceeds will help fund real-world clinical studies involving more than 1,500 cardiac arrest patients at leading European and US sites. This clinical program aims to generate evidence to support the potential integration of EOlife into standards of emergency.
We are profoundly grateful to our investors for their trust in our vision, to our clinical partners at leading US and European sites for supporting our studies, and to the entire dedicated Archeon team whose hard work brought us here. This milestone represents a meaningful step forward for emergency healthcare, and we could not have reached it without your commitment.
Read the full press release :
🇺🇸 https://archeon-medical.com/archeon-medical-secures-9m-series-a/
🇫🇷 https://archeon-medical.com/fr/archeon-medical-leve-7-5-millions-deuros-en-serie-a/